The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2018 | Finding the right targets for CAR T-cell therapy in AML
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, explains how CAR T-cell therapy might not prove effective in acute myeloid leukemia patients if healthy hematopoietic stem cells are targeted. His research group is now looking into special gene-modified autologous dendritic cells that have increased activity towards WT1, a tumor antigen that is expressed at high levels in various acute and chronic leukemias.
